New strategy for COVID-19 vaccination: targeting the receptor
4.5 (684) · $ 19.00 · In stock
Novel coronavirus structure reveals targets for vaccines and
Lipid-Based Poly(I:C) Adjuvants Strongly Enhance the Immunogenicity of SARS-CoV-2 Receptor-Binding Domain Vaccine
Recent Developments on Therapeutic and Diagnostic Approaches for
In search of a pan-coronavirus vaccine: next-generation vaccine
PDF) New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein
COVID-19 mRNA vaccines: Platforms and current developments
Why does COVID-19 disproportionately affect older people?
News & Comment Cellular & Molecular Immunology
PDF) Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2
COVID-19 Vaccines - Region of Durham
Tracking COVID-19 vaccines and therapeutics
Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein - ScienceDirect
